Workflow
TELA Bio, Inc. (TELA) Reports Q1 Loss, Tops Revenue Estimates
TELA BioTELA Bio(US:TELA) ZACKSยท2025-05-08 22:50

Group 1: Earnings Performance - TELA Bio reported a quarterly loss of $0.25 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.21, representing an earnings surprise of -19.05% [1] - The company posted revenues of $18.52 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 6.13%, compared to revenues of $16.6 million a year ago [2] - Over the last four quarters, TELA Bio has not surpassed consensus EPS estimates and has topped consensus revenue estimates only once [2] Group 2: Stock Performance and Outlook - TELA Bio shares have declined approximately 68.5% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.17 on revenues of $20.2 million, and for the current fiscal year, it is -$0.63 on revenues of $85.2 million [7] - The estimate revisions trend for TELA Bio is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Group 3: Industry Context - The Medical - Biomedical and Genetics industry, to which TELA Bio belongs, is currently in the top 33% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact TELA Bio's stock performance [5]